Jim Krenn

Jim Krenn

Education

University of Notre Dame (B.B.A., 2005)
Harvard Law School (J.D., 2008)

Bar Admissions

California

Jim Krenn has extensive experience representing public and private companies and investors in significant business transactions from formation through liquidity. His practice focuses on mergers and acquisitions, venture capital financings, and emerging company counseling.

Mr. Krenn advises clients on private and public acquisitions on both the buy-side and sell-side across numerous transaction structures, including equity purchases, asset purchases, mergers, acquisitions, and divestitures of divisions and subsidiaries, cross-border transactions, and auctions. He has represented buyers and sellers in acquisitions and divestitures ranging from $1 million to over $1 billion.

Mr. Krenn counsels emerging and established life science and technology companies in equity financings and general corporate matters, and angel, corporate, and venture capital investors in investments in such companies. Mr. Krenn has represented clients in over $2 billion in equity and debt financings ranging from seed rounds to $100 million plus later stage rounds.

In addition, Mr. Krenn represents public companies in public offerings, other capital markets transactions, and SEC reporting and compliance matters, and advises boards of directors on corporate governance issues.

Mr. Krenn has represented clients in a broad range of industries, including biopharmaceutical, artificial intelligence, medical device, e-commerce, cybersecurity, software, Internet, social media, semiconductor, unmanned aerial vehicles, agtech, consumer products, finance, cleantech, action sports, and energy.

Mr. Krenn was recognized as “Best of the Bar” by the San Diego Business Journal in 2015. Mr. Krenn received his J.D., cum laude, from Harvard Law School. Mr. Krenn received his B.B.A., summa cum laude, in finance from the University of Notre Dame, where he was a recipient of the Hamilton Finance Award and the Eugene D. Fanning Award for exceptional achievement in business communication.

Representative M&A and Venture Financing Matters:

MERGERS AND ACQUISITIONS

  • ACEA Biosciences, a medical instruments company, in its sale to Agilent Technologies (NYSE: A) for $250 million.
  • Adicet Bio, a biopharmaceutical company focused on the development of next-generation cell immunotherapies, in its cross-border acquisition of Applied Immune Technologies for an undisclosed sum.
  • Alaska Energy & Resources Company, the parent company of a regulated electric utility in Alaska, in its $170 million sale to Avista (NYSE: AVA).
  • Astute Medical, a medical diagnostic company focusing on high-risk medical conditions and diseases, in its $90 million sale to bioMérieux (EPA: BIM).
  • B. Riley Financial (NASDAQ: RILY), a diversified financial services company, in its $53 million private placement and merger with investment banking firm B. Riley & Co.
  • Biotix, a private equity-backed developer and manufacturer of laboratory consumables and liquid handling solutions, in its sale to Mettler-Toledo (NYSE: MTD) for an undisclosed sum.
  • California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple acquisitions.
  • Clean Energy Fuels (NASDAQ: CLNE), a provider of natural gas as an alternative fuel for vehicle fleets, in its sale for up to $180 million of components of its renewable natural gas business to BP (NYSE: BP). 
  • Cogent (NASDAQ: COGT), a biometric identification solutions provider, in its $943 million sale to 3M (NYSE: MMM).
  • Deere & Company (NYSE: DE), in its announced acquisition of the precision planning unit of Monsanto (NYSE: MON) for an undisclosed sum.
  • Mentor (NYSE: MNT), a leading supplier of medical products for the global aesthetic market, in its $1.12 billion sale to Johnson & Johnson (NYSE: JNJ).
  • Mitchell International, a developer of smart technology solutions that simplify and accelerate claims handling, repair processes, and pharmacy transactions, in its acquisition of Cogent Works for an undisclosed sum.
  • Wavestream, a provider of high power solid state amplifiers, in its $137 million sale to Spacenet, a subsidiary of Gilat Satellite Networks (NASDAQ: GILT).

VENTURE FINANCINGS

  • ACEA Biosciences, a developer of cell analysis instrumentation technologies, in its $30 million Series E Preferred Stock financing.
  • Adicet Bio, a biopharmaceutical company focused on the development of next-generation cell immunotherapies, in its Series A financing of up to $51 million.
  • Astute Medical, a medical diagnostic company focusing on high-risk medical conditions and diseases, in over $200 million of equity and debt financings.
  • California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple equity and debt financings.
  • Forward Ventures as an investor in multiple equity financings, convertible debt financings, and M&A transactions, including transactions involving HemaQuest Pharmaceuticals, LigoCyte Pharmaceuticals, Ambit Biosciences, and Syndax Pharmaceuticals.
  • Greenoaks Capital Partners and its affiliates as investors in over $100 million in equity financings, debt financings, and secondary transactions, including Coupang and several other prominent e-commerce companies.
  • Oak Investment Partners as an investor in multiple equity financings, including MobiTV and Brit Media.
  • Petuum, an artificial intelligence and machine learning software infrastructure provider, in its $93 million Series B financing.
  • Rakuten Aspyrian, a biotechnology company developing a new class of precision targeted oncologic drugs, in over $370 million of equity financings.
  • Solarflare Communications, a provider of application-intelligent networking I/O software and hardware platforms, in over $200 million of equity and debt financings.
  • VoloAgri, an agriculture technology company focused on seed genetics, in over $150 million of equity financings.
  • Western Digital Capital as an investor in multiple equity financings, including investments in Hightail and Upthere.

MoFo ScaleUp

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.